Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis

• Published in: Leukemia Vol. 36; no. 11; pp. 2596 - 2604
• Main Authors: Zhang, Hui, Bu, Chaoke, Peng, Zhiyong, Li, Guangchao, Zhou, Zhao, Ding, Wen, Zheng, Yongwei, He, Yingyi, Hu, Zhengbin, Pei, Kunlin, Luo, Min, Li, Chunfu
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.11.2022; Nature Publishing Group
• Subjects: 13/106; 13/109; 13/31; 59/5; 631/67/1059/2325; 631/67/1059/602; 64/60; 692/308/2779/109/1940; 82/1; Acute myeloid leukemia; Animals; Antigens; Autografts; Cancer Research; Children; Clinical trials; Critical Care Medicine; Cytokine Release Syndrome; Cytokines; Effectiveness; Health services; Hematology; Hematopoietic Stem Cell Transplantation; Immunotherapy; Immunotherapy, Adoptive - adverse effects; Immunotherapy, Adoptive - methods; Intensive; Internal Medicine; Lectins, C-Type; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Lymphocytes; Lymphocytes T; Medicine; Medicine & Public Health; Mice; Minimal residual disease; Oncology; Patients; Receptors, Chimeric Antigen; Remission; Remission (Medicine); Safety; Stem cell transplantation; Stem cells

C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia (AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti-CLL1-based CAR-T cells exhibited effective tumor-killing capacity in vitro and in AML-bearing mouse model. In this repor...